China Biologic Products Holdings Goodwill

China Biologic Products Holdings posts a goodwill of $330M as of December 2020. That compares with $310M in the prior-year period — up 6.9% year over year. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, China Biologic Products Holdings's goodwill was $310M. The latest reading is $330M — a 6.9% year-over-year increase (period ending December 2020). Use the history and growth charts on this page for a longer lookback.

Goodwill is one piece of China Biologic Products Holdings's financial statement story. At $330M, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for CBPO's goodwill usually means three checks: (1) trend versus prior periods, (2) level versus peers, and (3) consistency with growth and profitability. This page covers the first two; China Biologic Products Holdings's other metric pages and overview cover the third.

Judging China Biologic Products Holdings against Healthcare peers is usually better than using a market-wide rule of thumb. Business models inside Healthcare are more comparable, which makes gaps in goodwill easier to interpret. Start with $330M here, then scan peer and history charts to see if the gap is persistent.